By Peter Loftus
Eli Lilly, the world's biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast.
-- Sales of weight-loss drug Zepbound and diabetes drug Mounjaro rose in the fourth quarter.
-- Revenue from Zepbound leapt to $1.91 billion, up from $175.8 million a year earlier.
-- Mounjaro's revenue rose to $3.53 billion, from $2.63 billion a year earlier.
Investor confidence in the anti-obesity drug market's potential has been shaken in recent months, because sales of Zepbound and Novo Nordisk's Wegovy have come in lower than expected in some quarters. Both stocks are down since last summer.
Lilly had already previewed quarterly sales and given a 2025 revenue forecast last month. That hit the stock, because sales of Mounjaro and Zepbound were growing more slowly than expected.
Lilly's stock climbed nearly 1% premarket Thursday.
Overall, for the fourth quarter:
-- Revenue rose 45% to $13.53 billion. Aside from Mounjaro and Zepbound, sales also rose for cancer drug Verzenio and psoriasis drug Taltz.
-- Adjusted fourth-quarter earnings totaled $5.32 a share.
-- That topped the FactSet analysts' consensus estimate of $5.01 a share.
-- For 2025, Lilly predicts earnings of $22.50 to $24 per share, leaving room to beat the consensus forecast of $22.76.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
February 06, 2025 08:18 ET (13:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。